Alexandros Spyridonidis, MD, University of Patras, Patras, Greece, provides an overview of the latest developments in the prevention of graft-versus-host disease (GvHD). The approval of numerous treatments including ruxolitinib as well as cellular therapies being assessed in clinical trials will seek to improve outcomes in patients with chronic GvHD. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.